JointHealth™ express June 26, 2019
JointHealth™ insight – May/June 2019
Biosimilars: The next generation of biologic treatment for inflammatory arthritis patients
In this issue of JointHealth™ insight, we provide patients with inflammatory arthritis important facts to help them understand biosimilars and have an informed conversation with their healthcare provider.
Topics covered in this issue include:
JointHealth™ insight – May/June 2019
Biosimilars: The next generation of biologic treatment for inflammatory arthritis patients
In this issue of JointHealth™ insight, we provide patients with inflammatory arthritis important facts to help them understand biosimilars and have an informed conversation with their healthcare provider.
Topics covered in this issue include:
- British Columbia’s new ‘Biosimilar Initiative’ and what it means for patients
- The science behind biosimilars
- The definition of transitioning and Health Canada’s statement on biosimilar transitioning
- Patient experiences with transitioning in Europe and in Canada
- ACE’s new Biosimilars in Canada Guide- What Inflammatory Arthritis Patients Need to Know
- Societal benefits of biosimilars
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.